Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

Key Takeaway: Genmab has presented data on the EPCORE FL-1 subgroup, showing consistent efficacy and safety results for Epcoritamab when combined with Rituximab and Lenalidomide in patients with relapsed or refractory follicular lymphoma. The findings suggest a potential treatment option for this patient population, although specific details on outcomes were not provided.